Advances in polysaccharides of natural source of the anti-Alzheimer's disease effect and mechanism

Zhang, Zhiyuan; Wang, Shuai; Tan, Haining; Yang, Pei; Li, Yuanyuan; Xu, Lisha; Duan, Baoguo; Liu, Yuhong

doi:10.1016/j.carbpol.2022.119961

Cited by 20 publications

(8 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aβ usually exists in various forms of monomers, oligomers, polymers and insoluble fibrous aggregates. Additionally, soluble Aβ monomer and other Aβ monomer interactions gradually transform into oligomers, polymers and fibrous aggregates [ 41 ]. Aβ fiber aggregates further form Aβ plaques, which first accumulate in the cerebral cortex and then expand to other brain regions with the end-stage pathology, such as the hippocampus and basal forebrain [ 42 ].…”

Section: Pathological Hypothesis Of Alzheimer’s Diseasementioning

confidence: 99%

“…Because the main source of ROS in cells is from mitochondria, excessive accumulation of ROS will lead to the destruction of mitochondrial homeostasis and mitochondrial dysfunction [ 54 ]. In addition, in the early stages of AD, ROS has been shown to cause Aβ deposition and tau hyperphosphorylation in the brain [ 41 ].…”

Section: Pathological Hypothesis Of Alzheimer’s Diseasementioning

confidence: 99%

See 1 more Smart Citation

Anti-Neuroinflammatory Potential of Natural Products in the Treatment of Alzheimer’s Disease

Deng

Yan

et al. 2023

Molecules

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is an age-related chronic progressive neurodegenerative disease, which is the main cause of dementia in the elderly. Much evidence shows that the onset and late symptoms of AD are caused by multiple factors. Among them, aging is the main factor in the pathogenesis of AD, and the most important risk factor for AD is neuroinflammation. So far, there is no cure for AD, but the relationship between neuroinflammation and AD may provide a new strategy for the treatment of AD. We herein discussed the main etiology hypothesis of AD and the role of neuroinflammation in AD, as well as anti-inflammatory natural products with the potential to prevent and alleviate AD symptoms, including alkaloids, steroids, terpenoids, flavonoids and polyphenols, which are available with great potential for the development of anti-AD drugs.

show abstract

Section: Pathological Hypothesis Of Alzheimer’s Diseasementioning

confidence: 99%

Section: Pathological Hypothesis Of Alzheimer’s Diseasementioning

confidence: 99%

Anti-Neuroinflammatory Potential of Natural Products in the Treatment of Alzheimer’s Disease

Deng

Yan

et al. 2023

Molecules

View full text Add to dashboard Cite

show abstract

“…The majority of AD are characterized by late-onset and sporadic ( Andrade-Guerrero et al, 2023 ). At present, there is an incomplete understanding of the underlying mechanisms of AD, with its primary pathological characteristics involving abnormal phosphorylation of tau protein and excessive accumulation of amyloid beta (Aβ) ( Zhang, Wang, et al, 2022b ). Multiple hypotheses have been proposed to explain the etiology of AD, encompassing the tau protein hypothesis, amyloid hypothesis, cholinergic hypothesis, oxidative stress (OS) hypothesis, neuroinflammation hypothesis, apoptosis hypothesis, neurotrophic hypothesis, endoplasmic reticulum (ER) stress hypothesis, excitotoxicity hypothesis, and mitochondrial dysfunction hypothesis etc ( Liu et al, 2019a ; Serrano-Pozo, Das, and Hyman, 2021 ; Zhang, Wang, et al, 2022b ).…”

Section: Introductionmentioning

confidence: 99%

Mushroom-derived bioactive components with definite structures in alleviating the pathogenesis of Alzheimer’s disease

Jiang,

Song,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a complicated neurodegenerative condition with two forms: familial and sporadic. The familial presentation is marked by autosomal dominance, typically occurring early in individuals under 65 years of age, while the sporadic presentation is late-onset, occurring in individuals over the age of 65. The majority of AD cases are characterized by late-onset and sporadic. Despite extensive research conducted over several decades, there is a scarcity of effective therapies and strategies. Considering the lack of a cure for AD, it is essential to explore alternative natural substances with higher efficacy and fewer side effects for AD treatment. Bioactive compounds derived from mushrooms have demonstrated significant potential in AD prevention and treatment by different mechanisms such as targeting amyloid formation, tau, cholinesterase dysfunction, oxidative stress, neuroinflammation, neuronal apoptosis, neurotrophic factors, ER stress, excitotoxicity, and mitochondrial dysfunction. These compounds have garnered considerable interest from the academic community owing to their advantages of multi-channel, multi-target, high safety and low toxicity. This review focuses on the various mechanisms involved in the development and progression of AD, presents the regulatory effects of bioactive components with definite structure from mushroom on AD in recent years, highlights the possible intervention pathways of mushroom bioactive components targeting different mechanisms, and discusses the clinical studies, limitations, and future perspectives of mushroom bioactive components in AD prevention and treatment.

show abstract

“…Polysaccharides, as biopolymers widely present in our daily diet, hold great promise in the eld of AD prevention and treat. They can improve Alzheimer's disease through various mechanisms and have almost no toxic side effects [23].…”

Section: Introductionmentioning

confidence: 99%

Eucommiae cortex polysaccharides ameliorates learning and memory deficits in Alzheimer's disease mice by modulating gut microbiota and glutamate metabolism

Zhao,

Chai

et al. 2023

Preprint

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a chronic neurodegenerative disorder that is distinguished by impairments in learning and memory. The microbiota-gut-brain axis has emerged as a significant factor in the pathogenesis of Alzheimer's disease. Eucommiae cortex polysaccharides (EPs), one of the most abundant substances in the Eucommiae cortex, exhibit potential immunomodulatory and neuroprotective effects. In our study, we discovered that long-term intervention with EPs (0.25%, w/w in food) significantly improved learning and memory in 5×FAD mice, a well recognized mouse model for Alzheimer's disease. Additionally, EPs substantially reduce the generation and deposition of amyloid-beta (Aβ) plaques in AD Mice. EPs reshaped the composition of gut microbiota, increased the abundance of Erysipelotrichaceae, Allobaculum, Bacteroidota, and Muribaculaceae, which are related to gut immunity and short-chain fatty acids(SCFs) production that exert neuroprotective effects through the gut-brain axis. Furthermore, EPs administration was able to correct metabolic disorders in AD mice, particularly glutamate metabolism disturbances. Correlation analysis demonstrates a robust association between the restructuring of gut microbiota and alterations in glutamate metabolism. Importantly, EPs administration significantly inhibited neuroinflammation and restored the oxidative-antioxidative balance in the brains of AD mice, which are potential factors contributing to learning and memory impairments. Interestingly, EPs administration significantly activated autophagy. Our results demonstrate that EPs reshaped gut microbiota, corrected glutamate metabolism disturbances, and significantly alleviated learning and memory impairments in 5xFAD mice through the gut-brain axis. The natural extract EPs holds promising potential for the therapeutic management of neurodegenerative disorders.

show abstract

Advances in polysaccharides of natural source of the anti-Alzheimer's disease effect and mechanism

Cited by 20 publications

References 108 publications

Anti-Neuroinflammatory Potential of Natural Products in the Treatment of Alzheimer’s Disease

Anti-Neuroinflammatory Potential of Natural Products in the Treatment of Alzheimer’s Disease

Mushroom-derived bioactive components with definite structures in alleviating the pathogenesis of Alzheimer’s disease

Eucommiae cortex polysaccharides ameliorates learning and memory deficits in Alzheimer's disease mice by modulating gut microbiota and glutamate metabolism

Contact Info

Product

Resources

About